文献速递临床试验与 GCP真实世界研究与卫生经济

评估黑色素瘤监测摄影用于改善超高危和高危患者黑色素瘤早期检测的随机对照试验研究方案(IMAGE试验)

Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial).
PubMed 文献 · Trials · 2023-03-29

本研究为注册库为基础的、非盲、多中心、平行组随机对照试验,计划在澳大利亚三个州招募580例24个月内确诊原发性皮肤黑色素瘤的患者,1:1随机分为接受黑色素瘤监测摄影(MSP)联合常规临床监测的干预组与仅常规临床监测的对照组,主要结局为不必要的活检(假阳性)数量,并评估健康经济结局、生活质量与患者可接受性,旨在明确MSP的临床效能与成本效益。

要点

  • MSP包括二维或三维全身摄影联合标记数字皮肤镜,按预设间隔进行,可能减少不必要活检并促进黑色素瘤早期检测。
  • 主要结局为不必要的活检数量,即临床怀疑黑色素瘤而活检但组织病理学阴性者。
  • 试验计划在澳大利亚维多利亚州、新南威尔士州和昆士兰州招募580例参与者,随访3年。

核心结论

  • 该试验将确定MSP的临床效能、成本效益与可负担性,以促进国家和地方层面初级与专科医疗的政策决策。

研究设计与样本

  • 注册库为基础的、非盲、多中心、平行组随机对照试验,为期3年,计划招募580例参与者。
  • 参与者来自澳大利亚维多利亚州、新南威尔士州和昆士兰州,通过州癌症注册库或临床医生直接转诊招募,入组条件为原发性皮肤黑色素瘤诊断后24个月内。
  • 参与者按1:1随机分为干预组(常规临床监测联合MSP)或对照组(仅常规临床监测),大多数参与者继续由其常规照护提供者进行监测,随访频率取决于原发黑色素瘤分期和危险因素。

主要发现

  • 主要结局指标为不必要的活检数量,即临床检查(无论是否使用MSP)因怀疑黑色素瘤而活检但组织病理学结果阴性(假阳性)的病例数。
  • 次要结局包括健康经济结局、生活质量和患者可接受性的评估。
  • 两个子研究将探讨MSP在黑色素瘤诊断前高危患者中的获益,以及MSP在远程皮肤科环境与面对面临床环境中的诊断性能比较。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Melanoma surveillance photography (MSP) is a comprehensive surveillance method that comprises two- or three-dimensional total body photography with tagged digital dermoscopy, performed at prescribed intervals. It has the potential to reduce unnecessary biopsies and enhance early detection of melanoma, but it is not yet standard care for all high-risk patients in Australia. This protocol describes a randomised controlled trial (RCT) designed to evaluate the clinical impact and cost-effectiveness of using MSP for the surveillance of individuals at ultra-high or high risk of melanoma from a health system perspective. METHODS AND DESIGN: This is a registry-based, unblinded, multi-site, parallel-arm RCT that will be conducted over 3 years. We aim to recruit 580 participants from three Australian states: Victoria, New South Wales and Queensland, via state cancer registries or direct referral from clinicians. Eligible participants within 24 months of a primary cutaneous melanoma diagnosis will be randomised 1:1 to receive either MSP in addition to their routine clinical surveillance (intervention group) or routine clinical surveillance without MSP (control group). Most participants will continue surveillance with their usual care provider, and the frequency of follow-up visits in both groups will depend on the stage of their primary melanoma and risk factors. The primary outcome measure of the study is the number of unnecessary biopsies (i.e. false positives, being cases where a lesion is biopsied due to suspected melanoma on clinical examination, either with or without MSP, but the resulting histopathology finding is negative for melanoma). Secondary outcomes include the evaluation of health economic outcomes, quality of life and patient acceptability. Two sub-studies will explore the benefit of MSP in high-risk patients prior to a melanoma diagnosis and the diagnostic performance of MSP in the teledermatology setting compared to the en face clinical setting. DISCUSSION: This trial will determine the clinical efficacy, cost-effectiveness and affordability of MSP to facilitate policy decision-making at the national and local levels, across primary and specialist care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04385732 . Registered on May 13, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yan MK, Cust AE, Soyer HP, et al. Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial). Trials. 2023. PMID: 36991460. doi:10.1186/s13063-023-07203-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。